Quantitative analysis of influenza M2 channel blockers  by Astrahan, Peleg et al.
Biochimica et Biophysica Acta 1808 (2011) 394–398
Contents lists available at ScienceDirect
Biochimica et Biophysica Acta
j ourna l homepage: www.e lsev ie r.com/ locate /bbamemQuantitative analysis of inﬂuenza M2 channel blockers
Peleg Astrahan a,b, Ravenna Flitman-Tene a,1, Estelle R. Bennett a, Miriam Krugliak a,
Chaim Gilon b, Isaiah T. Arkin a,⁎
a Department of Biological Chemistry, The Alexander Silberman Institute of Life Sciences, The Hebrew University of Jerusalem, Edmund J. Safra Campus, Jerusalem, 91904, Israel
b Institute of Chemistry, The Hebrew University of Jerusalem, Edmund J. Safra Campus, Jerusalem, 91904, Israel⁎ Corresponding author.
E-mail addresses: peleg.asterhan@mail.huji.ac.il (P. A
(R. Flitman-Tene), estellerb@vms.huji.ac.il (E.R. Bennett
(M. Krugliak), gilon@vms.huji.ac.il (C. Gilon), arkin@hu
1 Present address: P.O. Box 306, Gilon, 20103, Israel.
0005-2736/$ – see front matter © 2010 Elsevier B.V. A
doi:10.1016/j.bbamem.2010.08.021a b s t r a c ta r t i c l e i n f oArticle history:
Received 7 July 2010
Received in revised form 26 August 2010
Accepted 31 August 2010




Channel blockerThe inﬂuenza M2 H+ channel enables the concomitant acidiﬁcation of the viral lumen upon endosomic
internalization. This process is critical to the viral infectivity cycle, demonstrated by the fact that M2 is one of
only two targets for anti-ﬂu agents. However, aminoadamantyls that block the M2 channel are of limited
therapeutic use due to the emergence of resistance mutations in the protein. Herein, using an assay that
involves expression of the protein in Escherichia coli with resultant growth retardation, we present
quantitative measurements of channel blocker interactions. Comparison of detailed Ks measurements of
different drugs for several inﬂuenza channels, shows that the swine ﬂu M2 exhibits the highest resistance to
aminoadamantyls of any channel known to date. From the perspective of the blocker, we show that
rimantadine is consistently a better blocker of M2 than amantadine. Taken together, such detailed and
quantitative analyses provide insight into the mechanism of this important and pharmaceutically relevant
channel blocker system.strahan), ravennaf@gmail.com
), miriamkru@savion.huji.ac.il
ji.ac.il (I.T. Arkin).
ll rights reserved.© 2010 Elsevier B.V. All rights reserved.1. Introduction
The function of M2 was the last step to be uncovered in the
infectivity cycle of the inﬂuenza virus [1]. Viral attachment and entry
into the cell are carried out through the activity of the hæmeagglu-
tinin protein. Membrane fusion followed by viral genome release
occurs after hæmeagglutinin undergoes a pH-triggered irreversible
conformational change in the acidic endosomes. In parallel M2's role
in the virus uncoating process is critical in that it enables the passage
of H+s from the acidic environment of the endosomal lumen into the
virus [2]. This weakens the interactions between the matrix protein
and the ribonucleoprotein core, enabling the release of the viral
genome into the cytoplasm. Additionally, in some viral strains, it was
not clear why hæmeagglutinin did not change its conformation in the
exocytic pathway where the pH is sufﬁciently low to cause the
conformational change. The answer to this question came upon
identifying the pH-dependent H+ channel activity of M2 [2], which
negates the activity of the Golgi H+ ATPase. We note that in many
tissues hæmeagglutinin internal cleavage takes place extracellularly
and hence a conformational change cannot take place in the exocytic
pathway.The homo-tetrameric structure of M2 has been investigated using
several techniques: X-ray crystallography [3], solid-state NMR [4] and
solution NMR [5]. The X-ray study, in detergent micelles [3], was of a
peptide that encompasses the transmembrane domain of the protein
(residues Ser22–Leu46). Furthermore, two structures were obtained:
one at pH 7.3 and another with amantadine at pH 5.3. Both structures
were shown to be highly similar to one another. The solid-state NMR
derived structural model was also obtained for the same transmem-
brane peptide, but this time in lipid bilayers [4] Finally, a solution
NMR study of a slightly longer peptide (residues Ser23–Lys60) with
rimantadine was reported in detergent micelles, as well [5]. The
peptide that was analyzed corresponded to residues Arg18–Lys60,
however, the N-terminal ﬁve residues were shown to be disordered.
Perhaps the reason for the intense interest in the M2 protein
described earlier, is that it is the molecular target of the anti-ﬂu drugs,
amantadine and rimantadine that block it H+ channel activity [2,6].
Yet, as a therapeutic option aminoadamantyls are not particularly
effective due to mutations that emerge in the M2 protein that render
the channel insensitive to aminoadamantyls [7] (see [8] for a recent
review). Therefore, it was our goal to provide a detailed analysis of the
activity of aminoadamantyls on variousM2 variants using a cell-based
assay that is both rapid and accurate.
A cell-based assay is another method to measure channel activity
aside from traditional electrophysiological approaches. In the assay
the channel is heterologously expressed in a host cell. Subsequently,
the host cell experiences growth retardation that is a direct function of
the permeabilization of its membrane by the non-native channel.
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the host's growth relative to poorly conducting species.
Kurtz and co-workers have constructed such a system to analyze
the activity of the inﬂuenza virus H+ channel [9]. Speciﬁcally, the
authors expressed the M2 channel in Saccharomyces cerevisiae, which
resulted in growth inhibition. Speciﬁcity was demonstrated by
showing that the growth inhibition could be relieved by the addition
of the anti-viral-speciﬁc M2 channel blocker amantadine. Finally, the
authors used this approach for a high-throughput screening effort
that resulted in the identiﬁcation of potentially new anti-viral agents.
Herein, we have extended the aforementioned approach, transi-
tioning to a different host — Escherichia coli, in order to make it a
quantitative tool that can be used for detailed analyses, as well as
high-throughput screening. The ease of genetic manipulation in E. coli,
compounded by the multitude of expression systems, enabled us to
tune the system, such that it yields quantitative results. Using the
aforementioned system, we were able to derive accurate Monod
coefﬁcients (half-saturation coefﬁcient or Ks) values for different
channel blockers, as well as to differentiate between channels from
different viral strains. In doing so wewere able to show that the swine
ﬂu channel is themost aminoadamantane-resistant channel known to
date.2. Materials and methods
2.1. Chemicals
Amantadine, Rimantadineand theHIS-Tag antibodywerepurchased
from Sigma-Aldrich laboratories. Isopropyl-β-D-thiogalactopyranoside
(IPTG) was purchased from Biochemika-Fluka (Buchs, Switzerland).
The pMal-p2x vector was purchased from New England Biolabs
(Ipswich, MA). pET-22b(+) plasmid and Tuner (DE3) cells were
purchased from Novagen (Gibbstown, NJ). DH10B bacteria cells were
purchased from Invitrogen.Westernblot reagentswere purchased from
BioRad.2.2. Plasmids and bacterial strains design
The Singapore M2 sequence was synthesized via a multistep PCR
protocol. This wild-type construct was designed according to the
Singapore H2N2 isolate, M2 sequence [7]. The genewas ﬂanked by the
NcoI and HindIII restriction sites, in the pUC57 plasmid. The sequence
was transferred with the former 2 restriction sites into the pMal-p2x
plasmid via XmnI and XbaI restriction sites, in frame to the carboxy
terminus of the MalE protein — following a poly Asn site. Different
bacterial strains were screened in this assay as hosts for the
aforementioned plasmid. As described in the Results and discussion
section, reproducible results were achieved with the DH10B and
Tuner (DE3) cells.
All other forms of the M2 proteins were obtained from mutations
of the Singapore wild-type strain with the Quick multi-Muatagenesis
kit from Stratagene (La Jolla, CA) and are listed in [7]. The BM2
channel sequence was according to [10].2.3. Cell growth
Cells bearing or lacking (as a reference) the ion channel genes
were incubated overnight from glycerol stocks in LB containing
100 μg/ml Ampicillin. Thereafter, the culture was diluted 100 fold and
the bacteria were grown until their O.D.600 reached 0.07–0.1, after
which IPTG was added to the growth culture. Cells were than divided
into 96 or 48 well ﬂat bottomed plates containing the different
treatments. The growth volume in the 48 or 96 well plates was 500 μl
and 100 μl, respectively.The plates were incubated for 16 h at 30 °C in a Synergy 2 multi-
detectionmicro-plate reader from Biotek (Winooski, VT) at a constant
high shaking rate. O.D.600 readings were recorded every 15 min.2.4. Western blotting
Bacteria were grown as described earlier, with 50μ M IPTG in-
duction, in the presence or absence of 100 μM Rimantadine for the
indicated times. From every time point, 0.5 ml was taken from the
growth culture and harvested by centrifugation. The pellet was
washed in PBS buffer (10 mM Na2HPO4 ⋅NaH2PO4, 120 mM NaCl and
2.7 mM KCl pH=7.4) and then resuspended in the SDS sample buffer
(2% SDS) at pH=6.8, containing 10% DTT, followed by heating to
60 °C for 20 min and intensive tip sonication (vibracell by sonics,
Newtown, CT).
The sample was then loaded onto a 10% polyacrylamide gel and
electrophoresed for 35 min under 30 mA. The gel was then blotted
onto a nitrocellulose membrane and visualization of the Singapore
wild-typeM2-MalE chimera was possible via blotting with an anti-
His-Tag antibody kit from Sigma-Aldrich laboratories, Israel.2.5. Inhibitory constant derivation
Monod coefﬁcients (Ks) were derived by measuring the dose
response effect of amantadine or rimantadine upon the maximal
growth rate of the host bacteria. The maximal growth rates were
obtained as the peaks in the graph indicating the change of the O.D.600
as a function of time. The resulting data were non-linearly ﬁt according
to the Monod equation relating the growth rate (R) to the drug
concentration:
R = Rmax drug½ 
Ks + drug½ 
Note the control data (i.e. data without any drug) were subtracted
from the results in order to serve as a reference.3. Results and discussion
The objective of this study was to quantitatively assess the
interaction between the inﬂuenza M2 channel, a critical component
of the viral life cycle [2], and its aminoadamantyl cognate blockers.We
therefore developed a cell-based assay in which the channel protein is
expressed in bacteria resulting in growth retardation. The effects of
channel blockers were then assayed by their ability to relieve the
aforementioned growth retardation.3.1. Protein expression
The ﬁrst step in the assay was to ensure proper heterologous
expression and reconstitution of the channel in E. coli. In order to
maintain successful incorporation into the bacterial inner membrane
we fused the M2 protein to the C-terminus of the maltose binding
protein. In Fig. 1, one can see the proﬁle of channel expression in the
bacteria as a function of time and the presence of an inhibitor. Sodium
dodecyl sulfate polyacrylamide gel electrophoresis of whole cell
lysates exhibits a band at the calculated molecular weight of the
chimeric protein (60 kDa). No protein is seen in the absence of
induction, while two hours or more post induction, expression is
clearly visible. Interestingly, the expression of the protein is enhanced
when the bacteria are grown in the presence of the anti-ﬂu drug
rimantadine. The reasons for this ﬁnding are elaborated subsequently.
Fig. 1. Western blot analysis of the malE-M2 (Singapore wild-type strain) chimeric
protein as a function of time post induction by 50 μM IPTG, and the presence of the anti-
ﬂu channel blocker rimantadine at 100 μM. Bacterial cells were examined by sodium
dodecyl sulfate polyacrylamide gel electrophoresis and blotted by an anti-His-Tag
antibody. Molecular weights are shown on the left.
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Following evidence that the M2 chimera is expressed in bacterial
cells, we examined the protein's effect upon the growth rate of the
bacteria. As seen in Fig. 2, bacteria that express the ion channel
(labelled as induced) are virtually incapable of growth as compared to
bacteria that do not harbor the M2 chimera (uninduced). However, it
is essential to establish that the growth impairment is a speciﬁc
function of the protein's channel activity and not just a general
deleterious effect due to over-expression of a heterologousmembrane
protein [11]. This was achieved by demonstrating that a speciﬁc
channel blocker of the protein — the anti-ﬂu agent rimantadine [7],
can appreciably alleviate the growth retardation (Fig. 2). Taken
together, we can conclude that the viral ion channel permeabilizes the
bacterial cell membrane, resulting in growth retardation, that can be
reversed by the activity of a speciﬁc channel blocker. The effect of theFig. 2. Growth curves (n=3) of bacteria expressing the M2 (Singapore wild-type
strain) channel (induced) and the inﬂuence of the anti-viral channel blocker
rimantadine (in gray), thereupon. Bacteria that do not express the ion channel
(uninduced) are shown as control. Induction takes place when the bacteria density
reaches an O.D.600 of 0.1. The error bars reﬂect the plus/minus the standard deviation
from three independent experiments. O.D.600 values were collected every 15 min. The
rimantadine concentration was 70 μM in order to ensure saturation.drug to nullify the channel's deleterious impact upon cell growth
might also be the reason why it promotes higher expression of the
protein in its presence (see Fig. 1). In addition, the drug itself does not
affect the growth rate of bacteria that do not harbor theM2 gene at all,
as shown in Fig. 3. Finally, we note that while the M2 channel is
activated in low pH [2], in neutral conditions under which the bacteria
were grown, it maintains a non-zero open probability [6]. It is this low
conductivity that hampers bacterial growth.
3.3. Channel strain effect
After demonstrating that the activity of the viral channel can be
speciﬁcally studied in the bacterial membrane, we set forth to
examine the effects of channels from various viral strains. Speciﬁcally,
we expressed the following ﬁve different H+ channels, each from a
different inﬂuenza strain: (i) Singapore, (ii) Rostock, (iii) Singapore
with a mutation of S31N, (iv) Swine ﬂu and (v) BM2 from inﬂuenza B.Fig. 3. Growth curves of bacteria that do not harbor the M2 gene and the inﬂuence of
the anti-viral channel blocker amantadine, thereupon. The concentration of amanta-
dine is as shown in the graph. The error bars reﬂect the plus/minus the standard
deviation from eight independent experiments.
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sensitive to aminoadamantyl drugs [12]. Furthermore, swine ﬂu is
known to contain the S31N mutation and hence was assumed to be
resistant to aminoadamantyl drugs [2]. Finally the BM2 channel from
inﬂuenza B is known to be resistant to aminoadamantyl drugs as well
[10].
As shown in Fig. 4, the different channels exhibit different sen-
sitivities to the aminoadamantyl drugs. The growth inhibition by the
channel from the Singapore strain is substantially relieved upon
addition of either rimantadine or amantadine. In contrast, the effect of
the drugs upon the growth retardation by channels from aminoada-
mantane-resistant viruseswas signiﬁcantly smaller. For example, only
a single mutation - S31N in the expressed channel diminished the
ability of aminoadamantyl drugs to relieve growth inhibition by more
than 50% (compare solid black line versus dotted gray line in Fig. 4).
Similarly, aminoadamantyl drugs exhibit poor growth retardation
relief for bacteria that express the BM2 channel from inﬂuenza B that
is known to be refractive to aminoadamantyl drugs [10].
However, it is important to note that the aforementioned assay is
sufﬁciently sensitive to detect the reduced aminoadamantane sen-
sitivity of the resistant channels such as the Singapore S31N mutant
[12]. In other words, the assay was able to detect even the reduced
levels of channel blocking which is important for identifying the full
dynamic range of resistance towards aminoadamantyls. In addition
this approach is suitable to high-throughput screening attempts, in
that such screens would be able to identify even poorly blocking
compounds, the activity of which can subsequently be enhanced by
further optimization efforts.
3.3.1. Swine ﬂu
One surprising outcome of our studywas that theM2 channel from
the swine ﬂu virus was shown to be the most resistant to both
aminoadamantyl drugs (dashed line in Fig. 4). Speciﬁcally, it was even
more resistant than the Singapore S31N mutant [12] and the BM2
channel from inﬂuenza B [10]. Current efforts in our group are aimedFig. 4. Growth curves of bacteria expressing different M2 channel variants in the
presence of rimantadine (n=4, top) or amantadine (n=3, bottom). Growth values
without any drug treatment (e.g. Fig. 2) are subtracted as control from the
aforementioned results. The different channel variants are: Singapore — black; Rostock
wt— gray; BM2— dotted black; Singapore S31N— dotted gray and swine ﬂu— dashed.
The concentration of both drugs was 70 μM. The error bars reﬂect the plus/minus the
standard deviation from independent experiments.at elucidating the mechanism of the enhanced resistance of the swine
ﬂu channel to aminoadamantyl drugs.
3.4. Drug effect
Having established that the assay can quantitatively detect
differences in sensitivity towards aminoadamantyl drugs between
the different channels, it was interesting to examine if differences
between various drugs can be observed as well. Here we compared
the growth retardation relief effects of the only two aminoadamantyl
drugs that are approved for prophylactic use: rimantadine and
amantadine. Detailed comparisons between the top and bottom
panels of Fig. 4 show that the activity of rimantadine is more
pronounced than amantadine [13–15]. Speciﬁcally, one can see that
regardless of the channel that is expressed, the bacteria were able to
grow to higher O.D.600 when rimantadine was added to the media in
comparison to amantadine. The different activities of the two drugs
(see Fig. 5) reﬂect the known advantage of rimantadine over
amantadine in channel blocking [13–18] that is mirrored in our assay.
3.5. Ks measurements
We then set forth to utilize the quantitative nature of the assay in
order to derive Ks values for various drugs and channels. Here we
calculated Ks values by measuring the dose response effect of
amantadine and rimantadine upon the maximal growth rate of the
host bacteria. As seen in Fig. 5, irrespective of the channel variant, or
the drug, the measured data ﬁt remarkably well to the Monod
equation. The derived Ks for the Singapore wild-type strain for
amantadine and rimantadine are 330 nM and 13 nM, respectively.
It is difﬁcult to compare our results to the isochronic apparent
inhibitory binding constants reported by Lamb and co-workers [6,15].
The reasons are that isochronic measurements by their very nature
depend on the time when the measurements are taken. Hence, direct
comparison to our procedure is not possible. In general one may note
that our study yields signiﬁcantly higher activities of aminoadamantyl
drugs relative to the isochronic approach. For example the Ks of
amantadine in the wild-type Singapore channel is 330 nM (Fig. 5) in
comparison to 16 μM in the isochronic study [15]. Furthermore, the
decrease in the S31N mutant sensitivity towards the drug in the
isochronic study is an order of magnitude — 16 to 200 μM [15]. In our
approach a much higher dynamic range is obtained (this time to
rimantadine) 13 nM to 5.4 μM. Finally, the differences noted earlier
may stem from the fact that the measurements in this study are of an
indirect nature — the effect of the drugs upon bacterial growth rather
than a direct measure of channel activity [6,15]. The advantage of
conducting such a cell-based assay stems from its ease of operation
and suitability to high-throughput screening. Herein, we have shown
that it is nonetheless highly quantitative, as well.
Similarly, it is difﬁcult to compare afﬁnities of the drug that were
measured to the M2 transmembrane peptide, either by ultracentri-
fugation [19] or surface plasmon resonance [20]. The reason being,
that the afﬁnity of the full length protein towards the drugs might
differ from that of the transmembrane segment. Indeed, the afﬁnities
that are measured by both of the aforementioned studies are much
lower than those measured in the current approach. Taken together,
the results that are described in this study represent one of the most
sensitive measurements of the activity of inﬂuenza channel blockers.
The last issue to consider is the dynamic range of our assay. As seen
in Fig. 5, our cell-based assay yields detailed Ks measurements in a
span of three orders of magnitude — from micro to nano-molar. This
aspect is critical to allow the assay to be used in high-throughput
screening since it ensures that one would be able to detect blockers
that are both highly efﬁcacious along-side marginally active com-
pounds. Finally, this assay is applicable to any channel as long as it can
Fig. 5. Dose response curves of amantadine and rimantadine for various M2 channels
(as indicated) upon the growth rate of the host bacteria. Note different drug
concentrations for each panel. Experimental values (black diamonds) were ﬁt
according to the Monod equation (black lines) yielding the Ks values as indicated.
The residuals are shown in gray squares. The error bars reﬂect the plus/minus the
standard deviation from three independent experiments.
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on the host.
4. Conclusion
In this study we report a simple system that can be used to assay
channel activity and inhibition thereof. In common with a previous
cell-based assay in S. cerevisiae [9], the assay involves expression ofthe channel in a microorganism host and channel activity is measured
by growth retardation. Herein, we have transitioned the system into a
simpler host — E. coli, that allowed us to screen a large number of
expression systems and host strains. This optimization resulted in an
assay that is quantitative with a large dynamic range on the one hand
and rapid and economic on the other. For example we were able to
detect marginal activities of aminoadamantyl drugs even in channels
that are clinically resistant towards them. In doing so we were able to
show that the channel for the swine ﬂu virus is the most resistant of
all known channels.Acknowledgements
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